文献速递乳腺癌

达罗他胺或卡培他滨治疗三阴性、雄激素受体阳性的晚期乳腺癌(UCBG 3-06 START):一项多中心、非比较性、随机、2期试验

Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial.
PubMed 文献 · Lancet Oncol · 2025-02-17

这项多中心、非比较性、随机、2期试验在法国45家医院纳入94例经治的晚期三阴性乳腺癌患者,按2:1随机接受达罗他胺或卡培他滨治疗。达罗他胺组16周临床获益率为29%,卡培他滨组为59%。达罗他胺组中,MAhigh肿瘤临床获益率为57%,其他肿瘤为16%(p=0.0020)。研究未达到达罗他胺在免疫组化AR阳性三阴性乳腺癌中的预设终点。

要点

  • 达罗他胺组16周临床获益率为29%,卡培他滨组为59%。
  • 达罗他胺组MAhigh肿瘤临床获益率57%,其他肿瘤16%(p=0.0020)。
  • 研究未达到达罗他胺在免疫组化AR阳性三阴性乳腺癌中的预设终点。

核心结论

  • 本研究未达到达罗他胺在基于免疫组化AR选择的三阴性乳腺癌患者中的预设终点。
  • 进一步基于RNA分析选择患者的研究可能有助于更好地识别对抗雄激素敏感的肿瘤。

研究设计与样本

  • 多中心、非比较性、随机、2期试验,在法国45家医院招募年龄≥18岁、ECOG体能状态0-1、既往最多接受过一线化疗的晚期三阴性乳腺癌女性患者。
  • 经中心确认三阴性乳腺癌和AR阳性(≥10%;SP107抗体)后,按2:1随机分配接受达罗他胺600 mg口服每日两次或卡培他滨最低1000 mg/m²每日两次(用药2周停1周),直至疾病进展、不可接受毒性、失访或撤回知情同意。
  • 随机化采用最小化法中心进行,按既往化疗线数分层;转录组分析将肿瘤分为AR活性高(MAhigh)和低(MAlow)组。
  • 主要临床终点为16周临床获益率(确认的完全缓解、部分缓解或疾病稳定);主要转化终点为达罗他胺组MAhigh肿瘤与其他所有肿瘤的临床获益率比较。
  • 分析按方案进行;试验注册号ClinicalTrials.gov NCT03383679,已停止招募。

主要发现

  • 2018年4月9日至2021年7月20日筛查254例女性,94例随机分配至达罗他胺组(n=61)或卡培他滨组(n=33),其中90例可进行疗效分析。
  • 数据截止2022年7月20日时中位随访时间为22.5个月(IQR 16.5-30.5)。
  • 达罗他胺组临床获益率为29%(17/58;90% CI 19-39),卡培他滨组为59%(19/32;90% CI 45-74)。
  • 达罗他胺组中,MAhigh肿瘤临床获益率为57%(12/21;95% CI 36-78),其他肿瘤为16%(5/31;95% CI 3-29;p=0.0020)。
  • 最常见的3级不良事件为手足红斑感觉异常综合征(达罗他胺组0/60 vs 卡培他滨组2例[6%])和头痛(达罗他胺组3例[5%] vs 卡培他滨组0例);未观察到4级或5级不良事件。

关键数值与推荐

  • AR阳性定义:免疫组化≥10%(SP107抗体)。
  • 达罗他胺剂量:600 mg口服每日两次。
  • 卡培他滨剂量:最低1000 mg/m²每日两次,用药2周停1周。
  • 主要临床终点:16周临床获益率(确认的完全缓解、部分缓解或疾病稳定)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究未达到达罗他胺在基于免疫组化AR选择的三阴性乳腺癌患者中的预设终点。
  • 进一步基于RNA分析选择患者的研究可能有助于更好地识别对抗雄激素敏感的肿瘤。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We proposed in 2005 that androgens replace oestrogens as the driver steroids in a subgroup of triple-negative breast cancer (TNBC) with androgen receptor (AR) expression called molecular apocrine (MA) or luminal androgen receptor (LAR). Here, we report the analysis of a clinical trial evaluating the antitumour activity of the anti-androgen darolutamide in MA breast cancer. Our aim was to assess the clinical benefit in patients with AR-positive TNBCs defined by immunohistochemistry and by RNA profiling. METHODS: In this multicentre, non-comparative, randomised, phase 2 trial, women aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0-1 and with advanced TNBC that was previously treated with a maximum of one line of chemotherapy were recruited from 45 hospitals in France. After central confirmation of TNBC status and AR positivity (≥10%; SP107 antibody), participants were randomly assigned (2:1) to receive darolutamide 600 mg orally twice daily or capecitabine minimum 1000 mg/m2 twice daily for 2 weeks on and 1 week off, until disease progression, unacceptable toxicity, lost to follow-up, or withdrawal of consent. Randomisation was done centrally using the minimisation procedure and was stratified according to the number of previous lines of chemotherapy. Transcriptomic analysis was used to classify tumours into groups with high and low AR activity (MAhigh and MAlow). The primary clinical endpoint was clinical benefit rate at 16 weeks (confirmed complete response, partial response, or stable disease). The primary translational endpoint was clinical benefit rate in the darolutamide group in MAhigh tumours versus all other tumours. Analyses were done per protocol. This trial is registered with ClinicalTrials.gov (NCT03383679), and is closed to recruitment. FINDINGS: Between April 9, 2018, and July 20, 2021, 254 women were screened and 94 were randomly assigned to darolutamide (n=61) or capecitabine (n=33), of whom 90 were evaluable for efficacy analyses. Median follow-up at the data cutoff on July 20, 2022, was 22·5 months (IQR 16·5-30·5). The clinical benefit rate was 29% (17 of 58; 90% CI 19-39) with darolutamide and 59% (19 of 32; 90% CI 45-74) with capecitabine. In patients treated with darolutamide, the clinical benefit rate was 57% (12 of 21; 95% CI 36-78) in MAhigh tumours, and 16% (five of 31; 95% CI 3-29; p=0·0020) in other tumours. The most common grade 3 adverse events were palmar-plantar erythrodysaesthesia syndrome (none of 60 in the darolutamide group vs two [6%] of 33 in the capecitabine group), and headache (three [5%] vs none). No grade 4 or 5 adverse events were observed. Drug-related serious adverse events occurred in three (5%) patients in the darolutamide group and three (9%) in the capecitabine group, which were toxicoderma (n=1) and headache (n=2) in the darolutamide group, and diarrhoea, general physical deterioration, and hepatic cytolysis in the capecitabine group (n=1 each). INTERPRETATION: This study did not reach its prespecified endpoint for darolutamide activity in patients with triple-negative breast cancer selected on the basis of immunohistochemistry for AR. Further studies selecting patients based on RNA profiling might allow better identification of tumours sensitive to anti-androgens. FUNDING: Bayer and Fondation Bergonié.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Bonnefoi H, Lerebours F, Pulido M, et al. Darolutamide or capecitabine in triple-negative, androgen receptor-positive, advanced breast cancer (UCBG 3-06 START): a multicentre, non-comparative, randomised, phase 2 trial. Lancet Oncol. 2025. PMID: 39978376. doi:10.1016/S1470-2045(24)00737-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。